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Clinical events following excimer laser angioplasty
or balloon angioplasty for complex coronary
lesions: subanalysis of a randomised trial
Yolande E A Appelman, Jan J Piek, William K Redekop, Pim J de Feyter, Jacques J Koolen,
George K David, Sipke Strikwerda, Jan G P Tijssen, Patrick W Serruys, E v Swijndregt,
Martin J C van Gemert, Kong I Lie
Abstract
Objectives—To compare clinical outcome
in patients with complex coronary lesions
treated with either excimer laser coronary
angioplasty (ELCA) or balloon angio-
plasty.
Patients and design—308 patients with
stable angina and a coronary lesion of
more than 10 mm in length were ran-
domised to ELCA (151 patients, 158
lesions) or balloon angioplasty (157 pa-
tients, 167 lesions). The primary clinical
end points were death, myocardial infarc-
tion, coronary bypass surgery, or repeated
coronary angioplasty of the randomised
segment during six months of follow up.
Subanalysis was performed to identify a
subgroup of patients with a beneficial
clinical outcome following ELCA or bal-
loon angioplasty.
Setting—Two university hospitals and one
general hospital.
Results—There were no deaths. Myocar-
dial infarction, coronary bypass surgery,
and repeated angioplasty occurred in 4.6,
10.6, and 21.2%, respectively, of patients
treated with ELCA compared with 5.7,
10.8, and 18.5%, respectively, of those
treated with balloon angioplasty. ELCA
did not yield a favourable clinical outcome
in subgroups of patients with long (more
than 20 mm) coronary lesions, calcified
lesions, small diseased vessels (<2.5 mm
reference diameter), or total coronary
occlusions. There was a worse clinical
outcome in patients with tandem lesions
treated with ELCA compared with balloon
angioplasty (9/18 v 3/26 lesions; p = 0.01);
while a trend towards an unfavourable
clinical outcome was found in patients
with vessels with a reference diameter of
more than 2.5 mm (23/66 v 13/63 lesions,
p = 0.07) and left circumflex coronary
lesions (12/41 v 6/42 lesions, p = 0.08).
Conclusions—The findings indicate a
worse clinical outcome in patients with
lesions of more than 10 mm treated with
ELCA compared with balloon angioplasty
who have tandem coronary lesions and in
those with vessels with a reference diam-
eter of more than 2.5 mm and left circum-
flex coronary lesions.
(Heart 1998;79:34–38)
Keywords: excimer laser angioplasty; laser assisted
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Excimer laser coronary angioplasty (ELCA)
was introduced as an alternative technique for
the treatment of obstructive coronary lesions
because of the unique features of the laser sys-
tem facilitating precise tissue ablation with
minimal adjacent injury.1–3 These characteris-
tics were considered optimal for application in
patients with diVuse coronary artery disease.
ELCA registries indicated favourable clinical
and angiographic outcomes in patients with
complex coronary lesions, such as long
coronary lesions (more than 10 mm), calcified
lesions, small diVusely diseased vessels
(<2.5 mm), ostial lesions, venous graft lesions,
or total coronary occlusions, compared with
those in patients treated by balloon
angioplasty.4–7 These promising results led to a
randomised trial in 1991 comparing the effects
ELCA and balloon angioplasty in patients with
stable angina and longer coronary lesions
(more than 10 mm in length).8 9 Similar initial
and long term clinical and angiographic
outcomes were reported for patients treated
with ELCA (followed by balloon angioplasty in
98% of the procedures) or balloon angioplasty.
The aim of the present study was to identify
a subgroup of patients with a beneficial clinical
outcome following either excimer laser assisted
balloon angioplasty or balloon angioplasty.
Patients and methods
Patients were randomised between September
1991 and November 1993 in the Amsterdam-
Rotterdam trial (AMRO) comparing ELCA
with balloon angioplasty in the treatment of
patients with stable angina and long (more
than 10 mm) native coronary lesions including
total or functional occlusion (thrombolysis in
myocardial infarction (TIMI) flow grade 0 or
I).10 The randomisation process, inclusion and
exclusion criteria, and procedural protocols of
the laser and balloon angioplasty procedures
have been described.9 The excimer laser
systems (wavelength 308 nm) used were
Dymer 200+ (Advanced Interventional Sys-
tems (AIS), Irvine, California, USA), with a
pulse duration of 210 ns and a repetition rate of
20 Hz, delivered by multifibre over wire laser
catheters with a diameter of 1.3, 1.6, or
2.0 mm, at a fluence of 45–65 mJ/mm2, and the
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Springs, Colorado, USA), which emits a pulse
duration of 135 ns at a repetition rate of 25 Hz,
delivered by 1.4, 1.7, or 2.0 mm laser cath-
eters, with a similar fluence. The 1.3 mm laser
catheter (AIS) was used after its introduction
in 1992. The 1.3/1.4 mm laser catheter was
used for vessels with a diameter of between
> 1.8 mm and < 2.3 mm; the 1.6/1.7 mm
laser catheter for vessels with a diameter of
between > 2.3 mm and < 3.0 mm; and the
2.0 mm laser catheter for vessels with a
diameter of > 3.0 mm. The 1.3/1.4 mm laser
catheter was used as the initial laser catheter in
total and functional occlusions. Adjunctive
balloon angioplasty was performed at the
operator’s discretion. Conventional balloon
angioplasty was performed according to the
standard clinical practice of the operator.
QUANTITATIVE ANGIOGRAPHY
Coronary angiography was performed in mul-
tiple projections, identically repeated before
and after the procedure and at six months’ fol-
low up. Angiography was carried out according
to previously published guidelines for auto-
mated analysis at the core laboratory using the
cardiovascular angiographic analysis system.11
CLINICAL AND ANGIOGRAPHIC FOLLOW UP
Patients were seen after one and six months for
interview, physical examination, and an elec-
trocardiogram. Follow up angiography was
performed after six months. Repeat interven-
tion was carried out if recurrent symptoms of
angina occurred or there was objective evi-
dence of myocardial ischaemia and a percent-
age diameter stenosis of more than 50% on
visual assessment of the randomised lesion, or
both.
END POINTS
Primary clinical end points were any of the
following events during six months, (± one
month) follow up: cardiac death, myocardial
infarction (based on the presence of at least two
of the following criteria: typical chest pain
and/or a rise in the serum concentration of
myocardial creatine kinase of more than twice
the normal upper limit and/or new pathological
Q wave formation on the electrocardiogram),
coronary bypass surgery, or a repeat angi-
oplasty because of recurrent symptoms of
angina and/or objective evidence of myocardial
ischaemia by positive exercise testing, all
presumably related to the randomised seg-
ment. Coronary bypass surgery included emer-
gency or elective bypass surgery. All clinical
events were reviewed by the critical event
committee, which was unaware of the treat-
ment assignment.
VARIABLES IN THE SUBGROUP ANALYSIS
Baseline clinical and angiographic variables
were related to the occurrence of clinical events
during six months’ follow up in both treatment
groups.
The following clinical variables were analysed:
sex, age, diabetes, hypertension, hyper-
cholesterolaemia, smoking status, previous myo-
cardial infarction, previous balloon angioplasty,
previous coronary bypass grafting, exertional
angina graded according to the Canadian
Cardiovascular Society classification,12 non-
exertional angina, and the extent of coronary
artery disease. The following angiographic vari-
ables were analysed: location of the randomised
lesion, type of lesion defined as ulcerated/
irregular contour of the lesion; calcified lesion
defined as fixed radiographic densities within
the randomised lesion, ranging from mild
(barely visible) to severe (spine density); eccen-
tric lesion defined as a highly asymmetric
appearance of the randomised stenosis in any
angiographic projection; tandem lesion defined
as sequential narrowing in the same randomised
coronary segment; grade of perfusion of the ran-
domised segment before intervention (TIMI
flow grade 0, I, II, or III); type of lesion accord-
ing to the modified American College of
Cardiology/American Heart Association task
force criteria,13 and estimated length of lesion.
The following quantitative variables were
analysed: interpolated reference diameter,
length of lesion, and percentage diameter
stenosis before angioplasty related to the
randomised lesion.
STATISTICAL ANALYSIS
Continuous variables (age, length of lesion,
reference diameter, percentage diameter steno-
sis) were divided in dichotomous variables by
cut oV points based on clinical relevance
reported in previous investigations. Age was
divided between those who were 70 years or
older and those who were less than 70;
reference diameter between vessels of 2.5 mm
or less and those of more than 2.5 mm; and
length of lesion between less than 20 mm or
20 mm or more. Lesion severity was analysed
in three arbitrary subgroups of increasing per-
centage diameter stenosis as 70%, 70–90%,
and 90%. Chi square analysis and Fisher’s
exact test for two by two tables were used to
compare dichotomous variables. Subgroup
analysis was performed to evaluate the relation
between baseline clinical and angiographic
variables and the occurrence of clinical events
in both groups. Clinical events occurring in
relation to baseline clinical and angiographic
variables were compared with the calculated
relative risk and 95% confidence intervals. All
Table 1 Clinical events occurring during six months’ follow up in the 308 patients





(n=157) Relative risk (95% CI) p value
Primary clinical end point 50 (33.1) 47 (29.9) 1.11 (0.80 to 1.93) 0.55
Death 0 0 —
Myocardial infarction 7 (4.6) 9 (5.7) 0.81 (0.31 to 2.12) 0.67
Q wave
Periprocedural 2 (1.3) 2 (1.3) 1.04 (0.15 to 7.29) 0.97
Follow up 2 (1.3) 1 (0.6) 2.08 (0.19 to 22.70) 0.54
Non-Q wave
Periprocedural 3 (2.0) 3 (1.9) 1.04 (0.21 to 5.07) 0.96
Follow up 0 3 (1.9) 0.15 (0.01 to 2.85) 0.09
CABG 16 (10.6) 17 (10.8) 0.98 (0.51 to 1.87) 0.95
Periprocedural 7 (4.5) 3 (1.9) 2.43 (0.64 to 9.21) 0.18
Follow up 9 (6.0) 14 (8.9) 0.67 (0.30 to 1.50) 0.32
Repeat angioplasty 32 (21.2) 29 (18.5) 1.15 (0.73 to 1.80) 0.55
Periprocedural 2 (1.3) 3 (1.9) 0.69 (0.12 to 4.09) 0.68
Follow up 30 (19.9) 26 (16.6) 1.20 (0.75 to 1.93) 0.45
Primary clinical end point: death, myocardial infarction, coronary artery bypass grafting (CABG),
or repeat angioplasty.
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statistical analyses were performed using the
statistical analysis system program. A p value of
less than 0.05 was considered significant.
Results
Baseline clinical and angiographic characteris-
tics were similar. A total of 308 patients (325
lesions) were randomised to either laser
angioplasty (151 patients, 158 lesions) or
balloon angioplasty (157 patients, 167 lesions).
Laser success, defined as a reduction of more
than 20% in percentage diameter stenosis by
visual assessment, was achieved in 107 (68%)
of 158 lesions treated by laser angioplasty. The
angiographic success rate, defined as a less than
50% diameter stenosis at the end of the proce-
dure by visual assessment, was achieved in 126
(80%) of the 158 lesions treated with laser
angioplasty and in 132 (79%) of the 167
lesions treated with balloon angioplasty. Laser
angioplasty was followed by additional balloon
angioplasty in 98% of procedures to obtain an
angiographic optimal result. Table 1 lists
periprocedural major clinical events and those
that occurred during six months’ follow up.
There was no mortality. The incidence of myo-
cardial infarction, coronary bypass grafting,
and repeat angioplasty was similar peripro-
cedurally and at six months in both groups.
Clinical follow up was completed in 98% of
patients in each group.
SUBGROUP ANALYSIS
Table 2 compares clinical outcome in patients
treated with laser angioplasty or balloon
angioplasty in relation to baseline clinical and
angiographic variables during six months’
follow up. The occurrence of a major clinical
event in association with diVerent clinical vari-
ables was similar in both groups.
The randomised lesion being located in the
left anterior descending coronary artery was
associated with a higher incidence of clinical
events independent of treatment allocation,
compared with the randomised lesion being
located in the right coronary artery or left cir-
cumflex.
At baseline, patients with lesions with a
reference diameter of more than 2.5 mm and
who were treated with laser angioplasty experi-
enced more clinical events than patients treated
with balloon angioplasty (p = 0.07). Location
of the randomised lesion in the left circumflex
artery was associated with a higher incidence of
clinical events in the laser angioplasty group
than in the balloon angioplasty group
(p = 0.08). Furthermore, treatment of a tan-
dem lesion with laser angioplasty was associ-
ated with a significant adverse clinical outcome
compared with that in patients treated with
balloon angioplasty (p = 0.01).
Twenty per cent of patients with diseased
vessels with a reference diameter of more than
2.5 mm assigned to laser angioplasty, had a
tandem lesion and 21% of patients had a left
circumflex coronary lesion. Moreover, 7% of
patients with a left circumflex coronary lesion
had a tandem lesion.
Discussion
ECLA: RANDOMISED VERSUS NON-RANDOMISED
Non-randomised ELCA registries show high
initial success rates and low complication rates
for complex coronary lesions that are consid-
ered less suitable for balloon angioplasty.4–7 14 15
In the present study, a subanalysis of the
randomised trial comparing excimer laser
angioplasty with balloon angioplasty for longer
(more than 10 mm) coronary lesions,9 excimer
laser angioplasty did not have a favourable
clinical outcome in patients with long (more
than 20 mm) coronary lesions, small diameter
vessels (<2.5 mm), calcified lesions, or total
coronary occlusions.
Our study diVers from the reports of ELCA
registries because of the randomised design of
the trial. First, the trial is a prospective collec-
Table 2 Analysis of the relation between important baseline clinical and angiographic
variables and the occurrence of clinical events in the 308 patients randomised to excimer







(95% CI) p value
Primary clinical end point 50/151 (33.1%) 47/158 (29.9%) 1.11 (0.80 to 1.54) 0.55
Clinical variables
Male 37/115 (32.1%) 32/114 (28.1%) 1.15 (0.77 to 1.70) 0.50
Female 13/36 (36.1%) 15/43 (34.9%) 1.04 (0.57 to 1.88) 0.91
>70 years 11/25 (44.0%) 11/28 (39.3%) 1.12 (0.59 to 2.12) 0.73
<70 years 39/126 (30.9%) 36/129 (27.9%) 1.11 (0.76 to 1.62) 0.59
Diabetes 6/15 (40.0%) 7/20 (35.0%) 1.14 (0.48 to 2.70) 0.76
Hypertension 21/57 (36.8%) 17/50 (34.0%) 1.08 (0.65 to 1.81) 0.76
Hypercholesterolemia 23/58 (39.7%) 18/59 (30.6%) 1.30 (0.79 to 2.14) 0.30
Smoking status
Never 15/41 (36.6%) 15/50 (30.0%) 1.22 (0.68 to 2.19) 0.51
Previous 25/74 (33.8%) 23/68 (33.8%) 1.00 (0.63 to 1.58) 1.00
Current 7/33 (21.2%) 7/34 (20.6%) 1.03 (0.41 to 2.62) 0.95
History of MI 22/70 (31.4%) 24/68 (35.3%) 0.89 (0.56 to 1.43) 0.63
History of BA 3/16 (18.8%) 4/25 (16.0%) 1.17 (0.30 to 4.56) 1.00
History of CABG 3/10 (30.0%) 2/13 (15.4%) 1.95 (0.40 to 9.54) 0.62
Exertional angina
CCS class I+II 16/56 (28.6%) 15/58 (25.9%) 1.10 (0.61 to 2.02) 0.75
CCS class III+IV 34/95 (35.8%) 32/99 (32.3%) 1.11 (0.75 to 1.64) 0.61
Extent of coronary artery
disease
Monovessel 27/83 (32.5%) 22/79 (27.8%) 1.17 (0.73 to 1.87) 0.52
Multivessel 23/68 (33.8%) 25/78 (32.1%) 1.06 (0.66 to 1.68) 0.82
Lesions n=158 n=167
Primary clinical end point 52/158 (32.9%) 51/167 (30.6%) 1.08 (0.78 to 1.48) 0.65
Angiographic variables
Location of lesion
LAD 25/61 (40.9%) 26/64 (40.6%) 1.01 (0.66 to 1.54) 0.97
RCA 15/56 (26.8%) 19/61 (31.2%) 0.86 (0.49 to 1.52) 0.60
LCx 12/41 (29.3%) 6/42 (14.3%) 2.05 (0.85 to 4.94) 0.08
Type of lesion
B2 30/83 (36.1%) 23/71 (32.4%) 1.12 (0.72 to 1.73) 0.63
C 22/74 (29.7%) 27/94 (28.7%) 1.04 (0.64 to 1.66) 0.89
Ulcerated 17/53 (32.1%) 15/55 (27.3%) 1.18 (0.66 to 2.11) 0.58
Calcified 9/33 (27.3%) 10/39 (25.6%) 1.06 (0.49 to 2.30) 0.88
Eccentric 30/100 (30.0%) 33/104 (31.7%) 0.95 (0.63 to 1.43) 0.79
Tandem 9/18 (50.0%) 3/26 (11.5%) 4.33 (1.36 to 13.83) 0.01
Estimated lesion length
10 to 20 mm 39/122 (31.9%) 35/109 (32.1%) 1.00 (0.68 to 1.45) 0.98
>20 mm 12/33 (36.4%) 11/44 (25.0%) 1.45 (0.74 to 2.88) 0.28
Grade of perfusion
0 + I 15/49 (30.6%) 12/54 (22.2%) 1.38 (0.72 to 2.65) 0.33
II + III 37/109 (33.9%) 39/113 (34.5%) 0.98 (0.68 to 1.42) 0.93
Quantitative variables
Reference diameter (mm)
<2.5 26/76 (34.2%) 35/88 (39.7%) 0.86 (0.58 to 1.29) 0.46
>2.5 23/66 (34.8%) 13/63 (20.6%) 1.69 (0.94 to 3.03) 0.07
Length (mm)
<20 25/79 (31.6%) 24/73 (32.9%) 0.96 (0.61 to 1.53) 0.87
>20 12/35 (34.3%) 14/50 (28.0%) 1.22 (0.64 to 2.33) 0.54
Diameter stenosis (%)
<70 30/98 (30.6) 35/106 (33.0%) 0.93 (0.62 to 1.39) 0.71
70 to 90 7/18 (38.9%) 4/18 (22.2%) 1.75 (0.62 to 4.95) 0.28
>90 15/42 (35.7%) 12/43 (27.9%) 1.28 (0.68 to 2.40) 0.44
Primary clinical end point: death, myocardial infarction (MI), coronary artery bypass grafting
(CABG), repeat angioplasty; CCS, angina classification according to the Canadian Cardiovascular
Society classification system;12 LAD, left anterior descending coronary artery; RCA, right
coronary artery; LCx, left circumflex coronary artery; Type of lesion, according to the modified
ACC/AHA Task Force criteria;13 Grade of perfusion, according to the TIMI study group.10
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tion of clinical and angiographic data moni-
tored in a meticulous fashion with almost com-
plete follow up. Second, quantitative coronary
analysis was performed by an independent core
laboratory, while the registries reported data
from core laboratories with incomplete follow
up or used data based on visual or quantitative
analysis performed at the participating
institutions.4–6 14 Third, the incidence of proce-
dural myocardial infarction in the present
study was determined routinely by measuring
the concentration of serum creatine kinase
after each procedure. In contrast, myocardial
infarction in the ELCA registries was detected
by either electrocardiographic criteria or enzy-
matic measurements, which were not per-
formed on a routine basis.4–6 14 15 This may
explain the observed diVerences. Our results
are similar to those in studies in which
enzymatic evaluation was determined routinely
as part of the procedure.16 17
ECLA: RANDOMISED CLINICAL TRIALS
A recently reported randomised trial compared
the clinical and angiographic results of rota-
tional atherectomy, ELCA, and balloon angio-
plasty, namely the excimer laser, rotational
atherectomy, and balloon angioplasty compari-
son (ERBAC) trial.18 Although a higher
proportion of patients with type C lesions or
long coronary lesions (more than 20 mm) were
included in our trial, both trials show a large
demand for additional balloon angioplasty
(93% in the ERBAC trial v 98% in the AMRO
trial). The results agree with those of our trial
showing no advantage of ELCA compared with
that of balloon angioplasty in terms of
procedural outcome and the number of
in-hospital events (12% in the ERBAC trial v
9% in the AMRO trial). The primary goals of
the ERBAC trial were procedural outcome and
in-hospital events and, as a consequence,
follow up angiography was not performed in all
patients (75% in the ERBAC trial v 93% in the
AMRO trial). Nevertheless, the incidence of
revascularisation procedures was higher in
patients treated with ELCA (46% in the
ERBAC trial v 26% in the AMRO trial), while
there was a trend towards an unfavourable
angiographic outcome in these patients. Data
from both trials indicates that ELCA, com-
pared with balloon angioplasty, does not result
in improved clinical and angiographic out-
come.
SUBGROUP ANALYSIS OF ECLA VERSUS BALLOON
ANGIOPLASTY FOR COMPLEX CORONARY LESIONS
The present study included patients with
longer (more than 10 mm) coronary lesions on
the basis that excimer laser angioplasty would
have a beneficial eVect on their outcome. A
subanalysis of the ELCA registries indicated a
favourable outcome in lesions of more than
20 mm in length, calcified lesions, total
coronary occlusions, and small diseased
coronary vessels.4–7 14 15 This reported benefit
could not be confirmed in our study.
A worse clinical outcome after treatment
with excimer laser angioplasty was seen in
patients with tandem lesions and there was a
trend towards an unfavourable clinical out-
come in those with vessels with a reference
diameter of more than 2.5 mm or left circum-
flex coronary lesions. An additional analysis
showed minimal overlap between the patient
groups with respect to these three variables,
indicating that they were independent factors
with an unfavourable clinical outcome follow-
ing excimer laser angioplasty. An explanation
for our findings is speculative. Most clinical
events occurred during follow up indicating
that the incidence of clinical events is related to
long term eVects following excimer laser angio-
plasty. After excimer laser application, fast
expanding and imploding vapour bubbles
induce damage in the vascular wall and
mechanical dilatation, which may result in
accelerated neointima hyperplasia,19 20 or unfa-
vourable vascular remodelling of the coronary
segment.21
The observation that excimer laser angio-
plasty results in an unfavourable clinical
outcome in vessels with a reference diameter of
more than 2.5 mm suggests that other tech-
niques, such as coronary stent implantation or
coronary atherectomy,22 are more appropriate
for treatment of larger sized vessels. The
observed unfavourable clinical outcome in left
circumflex coronary lesions requires further
investigation as it refers to a substantial
number of patients studied. Furthermore, the
incidence of clinical events is particularly low
in the balloon angioplasty group. The explana-
tion for the worse clinical outcome in tandem
lesions is speculative, as it refers to only a few
patients. Finally, the higher incidence of
clinical events irrespective of treatment after
intervention in the left anterior descending
coronary artery is in accord with results in
other reports.23
STUDY LIMITATIONS
This study concerns the results of a ran-
domised trial comparing ELCA versus balloon
angioplasty, although ELCA was followed by
balloon angioplasty in 98% of the procedures.
The frequent application of balloon angio-
plasty following ELCA relates to the recom-
mended size of the laser catheter in comparison
with the diameter of the reference segment.
Consequently, the results of this study involves
a comparison between laser assisted balloon
angioplasty and balloon angioplasty alone and
does not yield information on the outcome
after ELCA alone.
Furthermore, although this study has been
performed in the context of a randomised
clinical trial, it involves a post-hoc analysis. The
total number of patients studied in this trial is
relatively small, compared with the numbers
reported in some clinical ELCA registry
reports,15 16 and those recruited in multicentre
randomised trials of other devices.24
Recent insights have indicated that the
mechanical damage induced by excimer laser
angioplasty can be reduced by flushing with
saline before laser application.25 This proce-
dure removes blood situated in front of the
laser catheter and, consequently, absorption of
laser light by blood is reduced. Laser light is not
Excimer laser for coronary artery disease 37
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absorbed by saline,26 and this leads to the
decreased production of fast expanding and
imploding vapour bubbles and thus to the
reduction of vascular wall damage and less
dilatation of the coronary segment.20 This trial,
however, was conducted between 1991 and
1993 and consequently, no flushing protocol
was used. Other applications to optimise the
current laser technique, such as use of lower
energy fluence during the laser procedure,27
very slow passage with the laser catheter
through the lesion, multiplex laser,28 or a
modified laser catheter tip,29 are under investi-
gation and may improve the laser technique so
that it can be a useful device in the treatment of
coronary artery disease.
In conclusion, this randomised study shows
that in patients with coronary lesions of more
than 10 mm in length treated with excimer
laser angioplasty there are no subgroups with a
favourable clinical outcome compared with
those treated with balloon angioplasty.
The study was funded by the Dutch Health Insurance Executive
Board.
1 Grundfest WS, Litvack F, Forrester JS, et al. Laser ablation
of human atherosclerotic plaque without adjacent tissue
injury. J Am Coll Cardiol 1985;5:929–33.
2 Isner JM, Donaldson RF, Deckelbaum LI, et al. The
excimer laser: gross, light microscopic and ultrastructural
analysis of potential advantages for use in laser therapy of
cardiovascular disease. J Am Coll Cardiol 1985;6:1102–9.
3 Sartori M,Henry PD, Sauerbrey R, et al. Tissue interactions
and measurement of ablation rates with ultraviolet and vis-
ible lasers in canine and human arteries. Lasers Surg Med
1987;7:300–6.
4 Bittl JA, Sanborn TA, Tcheng JE, et al. Clinical success,
complications and restenosis rates with excimer laser
coronary angioplasty, the percutaneous excimer laser
coronary angioplasty registry. Am J Cardiol 1992;70:1533–
9.
5 Margolis JR, Metha SM. Excimer laser coronary angi-
oplasty. Am J Cardiol 1992;69:3–11F.
6 Cook SL, Eigler NL, Shefer A, et al. Percutaneous excimer
laser coronary angioplasty of lesions not ideal for balloon
angioplasty. Circulation 1991;84:632–43.
7 Bittl JA, Sanborn TA. Excimer laser-facilitated coronary
angioplasty. Relative risk analysis of acute and follow-up
results in 200 patients. Circulation 1992;86:71–80.
8 Strikwerda S, Koolen JJ, de Feyter PJ, et al. Excimer laser
coronary angioplasty in the Netherlands: preamble for a
randomized study. Am Heart J 1993;125:838–47.
9 Appelman YEA, Piek JJ, Strikwerda S, et al. Randomised
trial of excimer laser angioplasty versus balloon angioplasty
for treatment of obstructive coronary artery disease. Lancet
1996;347:79–84.
10 The TIMI Study Group. The thrombolysis in myocardial
infarction (TIMI) trial: phase I findings. N Engl J Med
1985;312:932–6.
11 Serruys PW, Foley DP, de Feyter PJ, eds. Quantitative
coronary angiography in clinical practice. Dordrecht: Kluwer
Academic, 1994.
12 Campeau L. Grading of angina pectoris. Circulation
1976;54:522–3.
13 Ellis SG, Vandormael MG, Cowley MJ, et al, and the Multi-
vessel Angioplasty Prognosis Study Group. Coronary mor-
phologic and clinical determinants of procedural outcome
with angioplasty for multivesssel coronary disease. Circula-
tion 1990;82:1193–202.
14 Litvack F, Eigler N, Margolis J, et al, for the ELCA investi-
gators. Percutaneous excimer laser coronary angioplasty:
results in the first consecutive 3,000 patients. J Am Coll
Cardiol 1994;23:323–9.
15 Baumbach A, Oswald H, Kvasnicka J, et al, and the coinves-
tigators of the European Coronary Excimer Laser Angi-
oplasty Registry. Clinical results of coronary excimer laser
angioplasty: report from the European coronary excimer
laser angioplasty registry. Eur Heart J 1994;15:89–96.
16 Klein LW, Kramer BL, Howard E, et al. Incidence and clini-
cal significance of transient creatine kinase elevations and
the diagnosis of non-Q wave myocardial infarction
associated with coronary angioplasty. J Am Coll Cardiol
1991;17:621–6.
17 Kugelmass AD, Cohen J, Moscuccie M, et al. Elevation of
the creatine kinase myocardial isoform following otherwise
successful directional coronary atherectomy and stenting.
Am J Cardiol 1994;74:748–54.
18 Reifart N, Vandormael M, Krajcar M, et al. Randomized
comparison of angioplasty of complex coronary lesions at a
single center. Excimer laser, rotational atherectomy, and
balloon angioplasty comparison (ERBAC) study. Circula-
tion 1997;96:91–8.
19 Van Leeuwen TG, Van Erven L, Meertens JH, et al. Origin
of arterial wall dissections induced by pulsed excimer and
mid-infrared laser ablation in the pig. J Am Coll Cardiol
1992;19:1610–18.
20 Van Leeuwen TG, Meertens JH, Velema E, et al. Intralumi-
nal vapour bubble induced by excimer laser pulse causes
microsecond arterial dilatation and invagination leading ot
extensive wall damage in the rabbit. Circulation 1993;93:
231–41.
21 Mintz GS, Pichard AD, Kent KM, et al. Intravascular ultra-
sound comparison of restenotic and de novo coronary
artery narrowings. Am J Cardiol 1994;74:1278–80.
22 Kuntz RE, Safian RD, Carroza JP, et al. The importance of
acute luminal diameter in determining restenosis after
coronary atherectomy or stenting. Circulation 1992;86:
1827–35.
23 Hermans WRM, Foley DP, Rensing BJ, et al. Usefulness of
quantitative and qualitative angiographic lesion morphol-
ogy, and clinical characteristics in predicting major adverse
cardiac events during and after native coronary balloon
angioplasty. Am J Cardiol 1993;72:14–20.
24 Topol EJ, Leya F, Pinkerton CA, et al. for the CAVEAT
Study Group. A comparison of directional atherectomy
with coronary angioplasty in patients with coronary artery
disease.N Engl J Med 1993;329:221–7.
25 Baumbach A, Haase KK, Rose C, et al. Formation of pres-
sure waves during in vitro excimer laser irradiation in whole
blood and the eVect of dilution with contrast media and
saline. Lasers Surg Med 1994;14:3–6
26 Gijsbers GHM,Van den Broecke DG, Sprangers RLH, et al.
EVect of force on ablation depth for a XeCl excimer laser
beam delivered by an optical fiber in contact with arterial
tissue under saline. Lasers Surg Med 1992;12:576–84.
27 Appelman YEA, Piek JJ, Verhoofstad GGAM, et al. Tissue
ablation and gas formation of two excimer laser systems: an
in vitro evaluation on porcine aorta. Lasers Surg Med 1996;
18:197–205.
28 Haase KK, Baumbach A, Spyridopoulos K, et al. Initial
clinical experience with a modified excimer laser for
coronary angioplasty. Lasers Med Sci 1994;9:7–15.
29 Hamburger JN, Gijsbers GHM, Lijmer JG, et al. 308nm
excimer laser tissue interaction using a modified multifiber
catheter [abstract]. J Am Coll Cardiol 1993; 21:385.
38 Appelman, Piek, Redekop, et al
 on 23 October 2006 heart.bmjjournals.comDownloaded from 
